Christopher Nutting, MD, PhD, on Head and Neck Cancer: Dysphagia-Optimized vs Standard IMRT
ASCO20 Virtual Scientific Program
Christopher Nutting, MD, PhD, of the Royal Marsden Hospital and Institute of Cancer Research, discusses phase III results from the first study to demonstrate the functional benefit of swallow-sparing intensity-modulated radiotherapy in oro- and hypopharyngeal cancers (Abstract 6508).
The ASCO Post Staff
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses early results on a cereblon E3 ligase modulator agent combined with dexamethasone in patients with relapsed or refractory multiple myeloma, with an overall response rate of 48%. The study is ongoing to further optimize dose and schedule (Abstract 8500).
The ASCO Post Staff
Sara A. Hurvitz, MD, of UCLA’s David Geffen School of Medicine, summarizes four breast cancer studies: KATHERINE, on adjuvant trastuzumab vs trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer; KAITLIN, on trastuzumab emtansine and pertuzumab vs trastuzumab, pertuzumab, and taxane after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer; TRAIN-2, on neoadjuvant chemotherapy with or without anthracyclines for HER2-positive disease; and PHERGain, on chemotherapy de-escalation using an FDG-PET/CT and pathologic response–adapted strategy in HER2-positive early breast cancer (Abstracts 500, 501, 502, and 503).
The ASCO Post Staff
Professor Lourdes Gil Deza, of the Instituto Oncológico Henry Moore, Buenos Aires, discusses her findings on the shortcomings of medical training when it comes to treating transgender patients, and the need to deepen clinical and communication skills to assist this population (Abstract 11002).
The ASCO Post Staff
As Thomas Powles, MD, PhD, of Queen Mary University of London, prepares to deliver his late-breaking presentation at the ASCO20 Virtual Scientific Program (LBA-1), he talks with Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, about current therapy: PD1/PDL1 inhibition in second-line treatment and as monotherapy in the first-line setting, as well as the concept of maintenance switch.
The ASCO Post Staff
Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduced toxicity, inconvenience, and cost (Abstract 4004).